Home › Funds › Octagon Capital Advisors LP › VRDN

Octagon Capital Advisors LP position in VRDN

VIRIDIAN THERAPEUTICS INC · Health Care

Octagon Capital Advisors LP reported holding 2,414,610 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$33.2M, representing 4.42% of its reported portfolio and ranking #7 among its reported holdings. Octagon Capital Advisors LP has disclosed VRDN holdings in 8 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)2.41M sh
Reported value held$33.15M
Portfolio Weight4.42%
First reportedQ3 2023
Last changeNew
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Octagon Capital Advisors LP's VRDN position evolved

Octagon Capital Advisors LP first disclosed a stake in VRDN in Q3 2023 at 1,067,143 shares (US$16.4M). The position peaked in Q3 2026 at 2,414,610 shares, worth US$33.2M. Across 8 filings, Octagon Capital Advisors LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 2,414,610 shares valued at US$33.2M. Notable position changes include a 42% trim in Q4 2023 (shares fell 20% over the following quarter), a 40% increase in Q3 2024 (shares fell 16% over the following quarter), a 48% trim in Q1 2025 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.07M $16.37M New
Q4 2023 620.00K $13.50M Reduce
Q1 2024 620.00K $10.86M Hold
Q2 2024 620.00K $8.07M Hold
Q3 2024 870.00K $19.79M Add
Q4 2024 870.00K $16.68M Hold
Q1 2025 450.00K $6.07M Reduce
Q3 2026 2.41M $33.15M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRDN and 13F data

VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 40 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Bellevue Group AG (US$146.4M), Kynam Capital Management, LP (US$126.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has Octagon Capital Advisors LP held VRDN?

Octagon Capital Advisors LP has disclosed VRDN holdings in 8 of the last 13 reported quarters, going back to Q3 2023.

What is Octagon Capital Advisors LP's current position in VRDN?

As of Q3 2026, Octagon Capital Advisors LP holds 2.41M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $33.15M, representing 4.42% of its reported portfolio and ranking #7.

Has Octagon Capital Advisors LP been buying or selling VRDN?

In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP newly opened its position in VRDN. The position peaked in Q3 2026 at 2.41M shares.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Bellevue Group AG, Kynam Capital Management, LP, among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.